Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA.

about

Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA.

Item

http://www.wikidata.org/entity/Q55226999

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Diagnostic accuracy of droplet ...... tion in circulating tumor DNA.

@en

Diagnostic accuracy of droplet ...... tion in circulating tumor DNA.

@nl

type

Item

label

Diagnostic accuracy of droplet ...... tion in circulating tumor DNA.

@en

Diagnostic accuracy of droplet ...... tion in circulating tumor DNA.

@nl

prefLabel

Diagnostic accuracy of droplet ...... tion in circulating tumor DNA.

@en

Diagnostic accuracy of droplet ...... tion in circulating tumor DNA.

@nl

P1476

Diagnostic accuracy of droplet ...... ation in circulating tumor DNA

@en

P2093

Bojiang Chen

http://www.w3.org/2001/XMLSchema#string

Chengdi Wang

http://www.w3.org/2001/XMLSchema#string

Jing Jin

http://www.w3.org/2001/XMLSchema#string

Rui Zhang

http://www.w3.org/2001/XMLSchema#string

Weimin Li

http://www.w3.org/2001/XMLSchema#string

Xiang Tong

http://www.w3.org/2001/XMLSchema#string

Ye Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies

Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.

Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

The diagnostic odds ratio: a single indicator of test performance.

Cancer heterogeneity: implications for targeted therapeutics.

P304

1209-1218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S161382

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Panwen Tian

P577

2018-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29844700

http://www.w3.org/2001/XMLSchema#string

P932

5962302

http://www.w3.org/2001/XMLSchema#string